Back to Authors

Bouras, Ernest

Mayo Clinic

Division of Gastroenterology, Mayo ClinicFlorida, USA.

Citations 2

Extent of eosinophilic esophagitis predicts response to treatment
Ghoz, Hassan , Valery, Jose R. , Nordelo, Katie, Malviya, Balkishan, Lacy, Brian E. , Francis, Dawn L., DeVault, Kenneth R. , Bouras, Ernest P., Krishna, Murli , Palmer, William C. , Francis, Dawn, DeVault, Kenneth, Bouras, Ernest, Stancampiano, Fernando F. , Lacy, Brian E.

Endoscopy International Open | August 24, 2021 | Volume: 09 | Issue: 08 | Pages: E1234-E1242

10.1055/a-1492-2650 Get It

Abstract Background and study aim The clinical impact of eosinophilic esophagitis (EoE) limited to the distal esophagus (Lim-EE) vs. diffuse involvement (Dif-EE) is unknown. This study compared clinical characteristics and outcomes of Lim-EE vs. Dif-EE. Patients and methods This retrospective, single-center study of patients with EoE between December 2011 and December 2019 evaluated treatment response based on repeated pathology and/or clinical improvement using comparative statistics. Results 479 patients were identified (126 Lim-EE, 353 Dif-EE). Lim-EE patients had a higher incidence of endoscopically identified esophagitis (23.0 % vs. 14.7 %; P = 0.04), were older (50.8 [SD 16.2] vs. 46.4 [SD 15.3] years; P = 0.007), and were more likely to present with iron deficiency anemia (5.6 % vs. 1.7 %; P = 0.05), dyspepsia (15.1 % vs. 8.8 %; P = 0.06) or for Barrett’s surveillance (10.3 % vs. 3.7 %; P = 0.02). Patients with Dif-EE presented more frequently with dysphagia (57.2 % vs. 45.2 %; P = 0.02). Both groups had similar proton pump inhibitor (87.2 % vs. 83.3 %; P = 0.37) and steroid (12.8 % vs. 21.4 %; P = 0.14) use. Patients with Lim-EE had a better clinicopathologic response (61.5 % vs. 44.8 %; P = 0.009). On multivariate analysis, EoE extent predicted treatment response with an odds ratio of 1.89 (95 % confidence interval 1.13–3.20; P = 0.02). However, treatment response based only on repeat biopsy results showed no statistical difference between Lim-EE (52.5 %) and Dif-EE (39.7 %; P = 0.15). Conclusions Lim-EE may represent a distinct phenotype separate from Dif-EE, with more overlap with gastroesophageal reflux disease and better treatment response.
Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice
Chris-Olaiya, Abimbola , Palmer, William C. , Lacy, Brian E. , Chirilă, Răzvan M. , Nikpour, Naveed, McLeod, Ethan, Ryan, Taylor, Maillis, Alexander , Vargas, Emily , Bouras, Ernest P., Stancampiano, Fernando, Lacy, Brian, Chirilă, Răzvan , Maillis, Alex, Bouras, Ernest, Stancampiano, Fernando F. , Heckman, Michael G.

Romanian Journal of Internal Medicine | July 10, 2020 | Volume: 58 | Issue: 4 | Pages: 228-232

10.2478/rjim-2020-0016 Get It

Abstract Introduction. Commonly prescribed medications are associated with various gastrointestinal (GI) side effects but few data are available on prescription medication use and polypharmacy in a gastroenterology outpatient practice. We aimed to examine the prevalence of polypharmacy, defined as the simultaneous use of 5 or more medications. Methods. A descriptive correlational study of consecutive outpatient consultations in 988 patients referred to a tertiary gastroenterology practice. Main outcome measurements were frequency of prescription medication use and polypharmacy. Results. The most common GI symptoms were abdominal pain (72%), nausea (57%), and constipation (53%). The frequency of polypharmacy was 10%. Eighty percent of patients took at least one medication and 60% took two or more. The most frequently used medication classes were proton pump inhibitors (43%), followed by benzodiazepines (30%), selective serotonin-reuptake or norepinephrine-reuptake inhibitors (28%), non-steroidal anti-inflammatory drugs (27%), and opioids (21%). Conclusion. There was a higher use of prescription medicine including antidepressants, and a lower frequency of polypharmacy in our study cohort compared to the general population. The use of medications may have contributed to the symptoms leading to our study’s population GI consultation.